Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 30 for “"ABT-263"”.

  1. THE EFFECT OF THE SENOLYTIC ABT-263 ON ANDROGEN DEPRIVATION-INDUCED SENESCENT PROSTATE TUMOR CELLS

    … exploited through the use of senolytics such as ABT-263 following ADT-induced senescence. ABT-263 selectively drives senescent, ADT-treated cells into apoptotic cell death while having minimal effect on non-senescent cells. Ongoing studies are designed to phenotypically characterize the recovered …

    vcu Repository record for THE EFFECT OF THE SENOLYTIC ABT-263 ON ANDROGEN DEPRIVATION-INDUCED SENESCENT PROSTATE TUMOR CELLS (opens in a new tab)

  2. Combining Noxa-Inducing Drugs with ABT-263 to Efficiently Increase Cell Death in Head and Neck Squamous Cell Carcinoma (HNSCC)

    … drugs: cisplatin, fenretinide, and ABT-263 (navitoclax). Both cisplatin and fenretinide are known to induce a BH3-only pro-apoptotic protein, Noxa, which binds to and inactivates multi-domain anti-apoptotic protein MCL-1 and release from its interaction with multi-domain …

    vcu Repository record for Combining Noxa-Inducing Drugs with ABT-263 to Efficiently Increase Cell Death in Head and Neck Squamous Cell Carcinoma (HNSCC) (opens in a new tab)

  3. Targeting BCL-2 Family Members in the Cell Death Pathway to Treat Head and Neck Cancer

    … inactivates anti-apoptotic MCL-1, while ABT-263 can inactivate other anti-apoptotic BCL-2 family members such as BCL-2 and BCL-XL. We used p53 inactive HN8 and HN12, p53 wild-type UMSCC1, and HPV-positive UMSCC47 human HNSCC cell lines and five mouse HNSCC cell lines. Cells were treated …

    vcu Repository record for Targeting BCL-2 Family Members in the Cell Death Pathway to Treat Head and Neck Cancer (opens in a new tab)

  4. NOVEL STRATEGIES IN HEAD AND NECK TUMOR THERAPY; CONTRIBUTION OF SENESCENCE IN THERAPY RESPONSE, AND RESISTANCE DEVELOPMENT AFTER CISPLATIN TREATMENT

    … In this study, we evaluated the effectiveness of ABT-263 (Navitoclax) and ARV-825, in the elimination of senescent tumor cells after cisplatin treatment. Navitoclax increased apoptosis by 3.3-fold (p ≤ 0.05) at Day 7 compared to monotherapy by cisplatin in HN30 and HN12 cells, however, it did not …

    vcu Repository record for NOVEL STRATEGIES IN HEAD AND NECK TUMOR THERAPY; CONTRIBUTION OF SENESCENCE IN THERAPY RESPONSE, AND RESISTANCE DEVELOPMENT AFTER CISPLATIN TREATMENT (opens in a new tab)

  5. Targeting the BCL-2 mediated anti-apoptotic pathway in infant acute lymphoblastic leukaemia

    … In this study, I investigated the effects of ABT-263, a novel small molecule drug that inhibits the pro-survival function of BCL-2, BCL-XL and BCL-W against a preclinical xenograft model of infant ALL that was developed as part of this thesis. The results demonstrate that ABT-263 is effective …

    unsw Repository record for Targeting the BCL-2 mediated anti-apoptotic pathway in infant acute lymphoblastic leukaemia (opens in a new tab)

  6. IDENTIFICATION OF EFFECTIVE SENOLYTIC STRATEGIES TO ENHANCE AND PROLONG RESPONSE TO STANDARD-OF-CARE CANCER TREATMENTS

    … here the effectiveness of the senolytic agent ABT-263 following therapy-induced senescence in both non-small cell lung cancer and prostate cancer. In etoposide-treated lung cancer, we demonstrate that the sequential combination of therapy-induced senescence and ABT-263 shifts the response to …

    vcu Repository record for IDENTIFICATION OF EFFECTIVE SENOLYTIC STRATEGIES TO ENHANCE AND PROLONG RESPONSE TO STANDARD-OF-CARE CANCER TREATMENTS (opens in a new tab)

  7. ssDNA Nanotubes as a Targeted Drug Delivery Vehicle for Triple Negative Breast Cancer

    … to perform targeted delivery of a senolytic, ABT-263, was also investigated, showing the promise of the nanotubes for dual delivery. The ssDNA amphiphiles were synthesized from a 10 nucleotide sequence attached to a dialkyl C16 tail via a C12 alkyl spacer, and have been previously shown to …

    jhu Repository record for ssDNA Nanotubes as a Targeted Drug Delivery Vehicle for Triple Negative Breast Cancer (opens in a new tab)

  8. Investigating the Role of Cellular Senescence on Vestibular Dysfunction in Repetitive Mild Traumatic Brain Injury

    … but did not receive impacts. The senolytic agent ABT-263 was administered via intraperitoneal injection to assess if removal of senescent cells could prevent the development of vestibular impairments and restore normal vestibular function in animals with existing rmTBI-induced vestibular deficits. …

    loyola-thes Repository record for Investigating the Role of Cellular Senescence on Vestibular Dysfunction in Repetitive Mild Traumatic Brain Injury (opens in a new tab)

  9. Unravelling the Influence of Donor Age on Renal Allograft Survival

    … durchgeführt. Die Auswirkungen des Senolytikums ABT-263 auf die Immunantwort des Empfängers wurden untersucht. Ergebnisse: Die Immunphänotypisierung ergab signifikante Unterschiede in der Popula-tion der Immunzellen zwischen jungen und gealterten Nieren. Gealterte Nieren wiesen eine höhere …

    fu-berlin Repository record for Unravelling the Influence of Donor Age on Renal Allograft Survival (opens in a new tab)

  10. Therapy-Induced Senescence in Cancer: Developing Senolytic-Based Combination Strategies to Delay Re-emergence of Triple-Negative Breast Cancer

    … challenge of TIS. Senolytic treatments with ABT-263 (navitoclax) produced only a transient clearance of senescent cells across the treatments with doxorubicin, hydroxy-peroxy-cyclophosphamide, 5-FU, paclitaxel and gemcitabine. Platinum-based agents yielded senescent populations that appeared …

    vcu Repository record for Therapy-Induced Senescence in Cancer: Developing Senolytic-Based Combination Strategies to Delay Re-emergence of Triple-Negative Breast Cancer (opens in a new tab)

  11. Targeting BCL-2 Family Proteins In Therapy Induced Senescent Cancer Cell Models

    … has shown that the dual BCL-XL/BCL-2 inhibitor ABT-263 is effective at selectively eradicating cancer cells that have been induced into senescence. However, ABT-263 was unable to pass clinical trials as it was shown to cause dose-limiting thrombocytopenia. Thrombocytopenia is a condition of low …

    vcu Repository record for Targeting BCL-2 Family Proteins In Therapy Induced Senescent Cancer Cell Models (opens in a new tab)

  12. Optimising Oncolytic Virotherapy and Immunotherapy for the treatment of Disseminated Colorectal Cancer

    … immunity, and BH3-mimetic inhibitors (ABT- 263), which antagonise the BCL-2 family of pro-survival proteins, may enhance CRC patient survival. Harnessing the potential immune and anti- cancer effects of these treatment modalities, alone and in combination, at primary tumour and sites of …

    whiterose Download PDF for Optimising Oncolytic Virotherapy and Immunotherapy for the treatment of Disseminated Colorectal Cancer (opens in a new tab)

  13. Impact of Renal Senescence on Kidney Allograft Outcome

    … ameliorated by applying the senolytic drug ABT-263 to the donor prior to transplantation, resulting in significantly lower levels of IFNγ and IL-10 of graft-infiltrating T cell subsets. Moreover, ABT-263 graft pre-treatment of the aged donor resulted in a significant improvement of graft …

    fu-berlin Repository record for Impact of Renal Senescence on Kidney Allograft Outcome (opens in a new tab)

  14. The Effects of Autophagy and Senescence on Sensitivity to Cisplatin in Head and Neck Cancer

    … Targeting of senescent cells with the senolytic ABT-263, a Bcl-2/Bcl-xl inhibitor, was effective in sensitizing cells to treatment with cisplatin, but cellular proliferation still occurred over time. Additionally, the HN30 cell line (p53 wild type) was compared to the HN12 line and experiments …

    vcu Repository record for The Effects of Autophagy and Senescence on Sensitivity to Cisplatin in Head and Neck Cancer (opens in a new tab)

  15. EXPLORING THE PRO-APOPTOTIC FUNCTION OF BIM

    … complex is resistant to BH3-mimic drug ABT-263 treatment while Bid does not. A Bcl-XL enhancer BH3 TCTP was also shown to interact with Bim-Bcl-XL and Bid-Bcl-XL complex differently, where a single mutation abolished its enhancement of Bid-Bcl-XL but not Bim-Bcl-XL. Closer investigation …

    mcmaster Repository record for EXPLORING THE PRO-APOPTOTIC FUNCTION OF BIM (opens in a new tab)

  16. The Heme-Regulated Inhibitor Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-Mimetics

    … therapeutics including the BH3-mimetic agents ABT-199 and ABT-263. The anti-malarial, dihydroartemisinin (DHA) translationally represses MCL-1 and synergizes with BH3-mimetics. To explore how DHA represses MCL-1, a genome-wide CRISPR screen identified that loss of genes in the heme synthesis …

    tenn-hsc Repository record for The Heme-Regulated Inhibitor Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-Mimetics (opens in a new tab)

  17. Building a metabolic bridge between glycolysis and sphingolipid biosynthesis : implications in cancer.

    … When combined with pre-clinical inhibitor ABT-263, this effect was augmented and production of proapoptotic sphingolipid ceramide increased. Taken together, we have shown that there exists a definitive link between glucose metabolism and GSL production, laying the groundwork for connecting …

    louisville Repository record for Building a metabolic bridge between glycolysis and sphingolipid biosynthesis : implications in cancer. (opens in a new tab)

  18. MODULATION OF AUTOPHAGY AND SENESCENCE TO ENHANCE THE RESPONSE TO THERAPY IN TRIPLE NEGATIVE BREAST CANCER

    … chemotherapy or radiation by the senolytic drug ABT-263 (Navitoclax). In summary, autophagy and senescence alone or in concert, can be induced by conventional anti-tumor modalities. Those processes can be modulated independently to achieve clearance of residual tumor cells following anti-cancer …

    vcu Repository record for MODULATION OF AUTOPHAGY AND SENESCENCE TO ENHANCE THE RESPONSE TO THERAPY IN TRIPLE NEGATIVE BREAST CANCER (opens in a new tab)

Page 1 of 2